Equities research analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to report ($1.17) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Global Blood Therapeutics’ earnings. The lowest EPS estimate is ($1.30) and the highest is ($0.98). Global Blood Therapeutics posted earnings per share of ($0.93) during the same quarter last year, which would suggest a negative year over year growth rate of 25.8%. The company is expected to issue its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Global Blood Therapeutics will report full-year earnings of ($4.09) per share for the current year, with EPS estimates ranging from ($4.27) to ($3.75). For the next year, analysts forecast that the company will report earnings of ($4.22) per share, with EPS estimates ranging from ($5.67) to ($2.83). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the company earned ($0.83) EPS.
In related news, insider Lesley Ann Calhoun sold 2,765 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $54.36, for a total value of $150,305.40. Following the transaction, the insider now owns 887 shares of the company’s stock, valued at $48,217.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Tricia Borga Suvari sold 3,249 shares of Global Blood Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $48.70, for a total transaction of $158,226.30. Following the transaction, the insider now directly owns 13,513 shares in the company, valued at approximately $658,083.10. The disclosure for this sale can be found here. Insiders sold a total of 14,698 shares of company stock valued at $711,058 in the last ninety days. 4.30% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the business. Perceptive Advisors LLC raised its position in shares of Global Blood Therapeutics by 4.5% during the second quarter. Perceptive Advisors LLC now owns 5,775,726 shares of the company’s stock valued at $303,803,000 after buying an additional 250,000 shares during the last quarter. Vanguard Group Inc. increased its position in Global Blood Therapeutics by 10.0% in the second quarter. Vanguard Group Inc. now owns 5,366,126 shares of the company’s stock worth $282,258,000 after purchasing an additional 485,866 shares during the last quarter. BlackRock Inc. increased its position in Global Blood Therapeutics by 4.8% in the second quarter. BlackRock Inc. now owns 4,482,728 shares of the company’s stock worth $235,792,000 after purchasing an additional 205,785 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Global Blood Therapeutics by 15.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 4,176,942 shares of the company’s stock worth $219,707,000 after purchasing an additional 572,808 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Global Blood Therapeutics by 13.6% in the second quarter. Bank of America Corp DE now owns 3,271,277 shares of the company’s stock worth $172,069,000 after purchasing an additional 392,104 shares during the last quarter. 98.19% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:GBT traded down $1.49 during trading on Monday, reaching $48.75. The company had a trading volume of 898,300 shares, compared to its average volume of 767,199. The company has a fifty day moving average of $48.61 and a two-hundred day moving average of $53.12. The stock has a market capitalization of $2.79 billion, a P/E ratio of -14.30 and a beta of 1.57. Global Blood Therapeutics has a 12 month low of $30.15 and a 12 month high of $64.94. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.04.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Recommended Story: How to Track your Portfolio in Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.